Neurogene (NASDAQ:NGNE – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.44, FiscalAI reports.
Neurogene Price Performance
Shares of NGNE stock opened at $25.31 on Monday. The firm has a market cap of $506.48 million, a P/E ratio of -5.03 and a beta of 1.75. Neurogene has a 1-year low of $15.93 and a 1-year high of $43.66. The firm’s 50-day simple moving average is $29.46 and its 200-day simple moving average is $27.94.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on NGNE. JPMorgan Chase & Co. began coverage on shares of Neurogene in a report on Thursday, October 8th. They issued an “overweight” rating and a $60.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of Neurogene from a “sell” rating to a “strong sell” rating in a report on Saturday, October 10th. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Neurogene in a research report on Wednesday, October 28th. Finally, William Blair raised shares of Neurogene to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Neurogene presently has a consensus rating of “Buy” and an average price target of $80.29.
Get Our Latest Analysis on NGNE
About Neurogene
Neurogene Inc (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.
Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis.
Featured Stories
- Five stocks we like better than Neurogene
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
